Contrasting Genocea Biosciences (GNCAQ) and The Competition
Contrasting Genocea Biosciences (GNCAQ) and The Competition
Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) is one of 277 publicly-traded companies in the "Biological products, except diagnostic" industry, but how does it contrast to its competitors? We will compare Genocea Biosciences to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.
基諾西亞生物科學（NASDAQ：GNCAQ-獲得評級）是「生物製品，除了診斷」行業的 277 家上市公司之一，但它與競爭對手有什麼對比？我們將根據其股息，分析師建議，估值，風險，盈利能力，盈利能力，收益和機構所有權的實力將 Genocea Biosciences 與相關公司進行比較。
Volatility & Risk
波動性和風險
Genocea Biosciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Genocea Biosciences' competitors have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.
基諾西亞生物科學的測試版為 1.99，這意味著其股價比標普 500 更波動 99％。相比之下，Genocea 生物科學的競爭對手的測試版為 0.97，這意味著他們的平均股價比標普 500 少波動性 3％。
Analyst Recommendations
分析師推薦
This is a breakdown of current ratings and target prices for Genocea Biosciences and its competitors, as provided by MarketBeat.
這是根奧西亞生物科學及其競爭對手的當前評級和目標價格的細分，由 MarketBeat 提供。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genocea Biosciences | 0 | 0 | 0 | 0 | N/A |
| Genocea Biosciences Competitors | 907 | 3883 | 10765 | 161 | 2.65 |
| 銷售評級 | 保留評分 | 購買評級 | 強大的買入評級 | 評級分數 | |
| 赫諾西亞生物科學 | 0 | 0 | 0 | 0 | N/A |
| 生物科學競爭對手 | 907 | 3883 | 10765 | 161 | 2.65 |
Earnings and Valuation
收益及估值
This table compares Genocea Biosciences and its competitors top-line revenue, earnings per share and valuation.
該表比較 Genocea 生物科學及其競爭對手的頂級收入，每股收益和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Genocea Biosciences | $1.64 million | -$33.20 million | 0.00 |
| Genocea Biosciences Competitors | $777.30 million | $140.96 million | -2.15 |
| 總收入 | 淨收入 | 市盈比率 | |
| 赫諾西亞生物科學 | 一百六十四萬元 | -33.2 億美元 | 0.00 |
| 生物科學競爭對手 | 777.30 百萬美元 | 一億四千九十六萬美元 | -2.15 |
Genocea Biosciences' competitors have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
吉諾西亞生物科學的競爭對手具有比 Genocea 生物科學更高的收入和收益。Genocea 生物科學的交易價格比競爭對手更高，這表明它目前比其行業中的其他公司更昂貴。
Institutional and Insider Ownership
機構和內幕所有權
0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 46.3% of shares of all "Biological products, except diagnostic" companies are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 16.3% of shares of all "Biological products, except diagnostic" companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
0.6％ 的 Genocea 生物科學股份由機構投資者持有。相比之下，所有「生物製品，診斷除外」公司的股份的 46.3％ 由機構投資者持有。Genocea 生物科學股份的 1.6％ 由公司內部人員持有。相比之下，所有「生物製品（診斷除外）」公司的股份的 16.3％ 由公司內部人員持有。強大的機構擁有權表明，大型資金經理，捐贈基金和對沖基金認為股票在長期內表現會超越市場。
Profitability
盈利
This table compares Genocea Biosciences and its competitors' net margins, return on equity and return on assets.
該表比較了 Genocea 生物科學及其競爭對手的淨利潤率，股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Genocea Biosciences | N/A | N/A | N/A |
| Genocea Biosciences Competitors | -4,576.26% | -103.48% | -37.14% |
| 淨利潤 | 權益回報率 | 資產回報率 | |
| 赫諾西亞生物科學 | N/A | N/A | N/A |
| 生物科學競爭對手 | -4,576.26% | -103.48% | -37.14% |
Genocea Biosciences Company Profile
基諾西亞生物科學公司簡介
(Get Rating)
(取得評分)
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Genocea 生物科學公司從事癌症免疫療法的開發和商業化。該公司使用其專有技術平台 ATLAS，根據實際的人體免疫反應來識別 T 細胞與臨床相關的抗原。其候選產品包括 GEN-011（一種研究性採用性 T 細胞療法）和 GEN-009（一種新抗原癌症疫苗）。該公司由羅伯特·保爾和凱文·比特曼於 2006 年 8 月 16 日成立，總部位於麻薩諸塞州劍橋。
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收赫諾西亞生物科學日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Genocea 生物科學和相關公司的最新新聞和分析師評級的簡要每日摘要。